Gary Whale
Technik-/Wissenschafts-/F&E-Leiter bei ZURA BIO LIMITED
Vermögen: 167 747 $ am 30.04.2024
Profil
Gary Whale is currently the Chief Technology Officer at Zura Bio Ltd.
Prior to his current position, he served as the Chief Operating Officer at VHsquared Ltd.
from 2018 to 2020 and as the Vice President & Global Head-Technical Operations at EUSA Pharma (UK) Ltd.
from 2020 to 2022.
Dr. Whale obtained his undergraduate and graduate degrees from the University of London and holds a doctorate from The Robert Gordon University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZURA BIO LIMITED CLASS A
0,11% | 25.03.2024 | 46 339 ( 0,11% ) | 167 747 $ | 30.04.2024 |
Aktive Positionen von Gary Whale
| Unternehmen | Position | Beginn |
|---|---|---|
| ZURA BIO LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2023 |
Ehemalige bekannte Positionen von Gary Whale
| Unternehmen | Position | Ende |
|---|---|---|
EUSA Pharma (UK) Ltd.
 EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2022 |
VHsquared Ltd.
 VHsquared Ltd. BiotechnologyHealth Technology VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom. | Geschäftsführer | 01.01.2020 |
Ausbildung von Gary Whale
| University of London | Graduate Degree |
| The Robert Gordon University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ZURA BIO LIMITED | Health Technology |
| Private Unternehmen | 2 |
|---|---|
VHsquared Ltd.
VHsquared Ltd. BiotechnologyHealth Technology VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom. | Health Technology |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Distribution Services |
